fbpx Press Releases | Heart Rhythm

Press Releases

New Ablation Technique Helps Treat Patients With Inappropriate Sinus Tachycardia
July 30, 2021 - A recent study unveiled a novel sinus node ablation technique that provides a safe and effective treatment option for patients suffering from symptomatic, drug-resistant inappropriate sinus tachycardia (IST). Results of the Susruta-IST Registry were presented as a late-breaking clinical trial at Heart Rhythm 2021.

First In-Human Results Reveal Novel Ice Catheter Provides Enhanced Visualization During Atrial Fibrillation Procedures
July 30, 2021 - Findings from a new, multi-center clinical trial reveal a novel 4- Dimension (4D) ICE catheter provides a simple, intuitive field of view during catheter ablation and left atrial appendage closure procedures. The results from the first in-human clinical study were presented as a late-breaking clinical trial as part of Heart Rhythm 2021.

New Clinical Trial Shows Increased Risk of Cardiac Events Among Women with Long QT Syndrome Taking Oral Contraceptives
July 30, 2021 - A new study shows direct oral anticoagulants (DOACS) are more effective than aspirin (ASA) in reducing cerebrovascular events (CVE), including transient ischemic attack and stroke in patients undergoing ventricular tachycardia using radiofrequency catheter ablation (RFA). Results of the STROKE-VT trial were presented as a late-breaking clinical trial as part of Heart Rhythm 2021.

Catheter Ablation Shown To Be Cost-Effective For Patients In Need of Treatment For Irregular Heartbeats
July 30, 2021 - A new analysis of the Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial examines cost-effectiveness of catheter ablation compared to drug therapy. CABANA is the largest trial comparing catheter ablation to drug therapy and this is first analysis on costs and cost effectiveness of ablation using patient-level data. Findings from the economic analysis were presented as a late-breaking clinical trial as part of Heart Rhythm 2021.

Early Catheter Ablation of Ventricular Tachycardia Outperforms Conventional Medical Therapy in Patients at Risk for Sudden Death
July 29, 2021 - Results from an international clinical trial show a significant reduction in risk of ventricular tachycardia (VT) recurrence, cardiovascular hospitalization, and death when catheter ablation is used as an early first-line treatment for patients with structural heart disease. Led by study coordinating center, the University of Chicago, The PAUSE-SCD trial is the first VT ablation trial to include patients with nonischemic cardiomyopathy and to be conducted across Asia. Findings of this landmark trial were presented today as late-breaking science during Heart Rhythm 2021.

New Clinical Trial Finds Human Oversight ECG Monitors Outperform AI-Dependent Monitoring
July 29, 2021 - Results from a new clinical trial find human-oversight dependent continuous electrocardiography (ECG) monitors to more accurately detect significant arrhythmias than mobile cardiac telemetry (MCT). Findings from this clinical trial were presented today as late-breaking science during Heart Rhythm 2021.

Use of Oral Anticoagulants Following Ablation Shown to Help Reduce Risk of Stroke in High-Risk Patient Population
July 29, 2021 - A new study shows direct oral anticoagulants (DOACS) are more effective than aspirin (ASA) in reducing cerebrovascular events (CVE), including transient ischemic attack and stroke in patients undergoing ventricular tachycardia using radiofrequency catheter ablation (RFA). Results of the STROKE-VT trial were presented as a late-breaking clinical trial as part of Heart Rhythm 2021.